Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)CD8(+) T-cell response is critical in the pathogenesis of cerebral malaria during blood-stage. Our group and other have been shown that angiotensin II (Ang II) and its receptor AT(1) (AT(1)R), a key effector axis of renin-angiotensin system (RAS), have immune regulatory effects on T cells. Previously, we showed that inhibition of AT(1)R signaling protects mice against the lethal disease induced by Plasmodium berghei ANKA infection However, most of the Ang II/AT(1)R actions were characterized by using only pharmacological approaches, the effects of which may not always be due to a specific receptor blockade. In addition, the mechanisms of action of the AT(1)R in inducing the pathogenic activity of Plasmodium-specific CD8(+) T cells during blood-stage were not determined. Here, we examined how angiotensin II/AT1R axis promotes the harmful response of Plasmodium-specific CD8(+) T-cell during blood-stage by using genetic and pharmacological approaches. We evaluated the response of wild-type (WT) and AT1R(-/-) Plasmodium-specific CD8(+) T cells in mice infected with a transgenic PbA lineage expressing ovalbumin; and in parallel infected mice receiving WT Plasmodium-specific CD8(+) T cells were treated with losartan (AT(1)R antagonist) or captopril (ACE inhibitor). Both, AT(1)R(-/-) OT-I cells and WT OT-I cells from losartan- or captopril-treated mice showed lower expansion, reduced IL-2 production and IL-2R? expression, lower activation (lower expression of CD69, CD44 and CD160) and lower exhaustion profiles. AT(1)R-/- OT-I cells also exhibit lower expression of the integrin LFA-1 and the chemokine receptors CCR5 and CXCR3, known to play a key role in the development of cerebral malaria. Moreover, AT1R(-/-) OT-I cells produce lower amounts of IFN-gamma and TNF-alpha and show lower degranulation upon restimulation. In conclusion, our results show the pivotal mechanisms of AT(1)R-induced harmful phenotype of Plasmodium-specific CD8(+) T cells during blood-stage malaria.7Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [57.3695/2008-3, 57.3767/2008-4, 471771/2013-9, 456997/2014-8]Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/110.551/2010, 111681/2013, E-26/102.170/2013, E-26/201.197/2014]Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)